Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 9Neoplasms 8Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 5Esophageal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Solid Cancers 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Cholangiocarcinoma 2Breast Neoplasms 2Bites and Stings 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immune-Related Adverse Events × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT07453342 2026-03-06

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Peking Union Medical College Hospital

Recruiting
500 enrolled

Immune-Related Adverse Events

Data powered by HemOnc (CC BY 4.0) Colophon âš¡